Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003993 · ClinicalTrials.gov registry record · Phase 1
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
A Phase 1 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00003993 is a Phase 1 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 24 participants.
The verdict
NCT00003993, a Phase 1 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining chemotherapy and interleukin-2 may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-2 when given together with bryostatin 1 in treating patients with refractory solid tumors or lymphoma.
Interventions
- BIOLOGICAL aldesleukin
- DRUG bryostatin 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1999-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003993
The ClinicalTrials.gov registry entry for NCT00003993 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aldesleukin is the first listed.
NCT00003993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003993 about?
NCT00003993 is a clinical study titled "Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining chemotherapy and interleukin-2 may kill more cancer cells. PURPOSE: This phase I trial is...
What is the current status of trial NCT00003993?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 1999-09.
What interventions are being tested in trial NCT00003993?
The interventions under investigation include: aldesleukin (BIOLOGICAL), bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00003993?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.